HLS Therapeutics Debt
| HLS Stock | CAD 3.52 0.04 1.12% |
HLS Therapeutics has over 87.62 Million in debt which may indicate that it relies heavily on debt financing. At this time, HLS Therapeutics' Net Debt is very stable compared to the past year. As of the 4th of December 2024, Long Term Debt is likely to grow to about 86.2 M, while Short and Long Term Debt Total is likely to drop about 51.5 M. With a high degree of financial leverage come high-interest payments, which usually reduce HLS Therapeutics' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
HLS Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. HLS Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps HLS Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect HLS Therapeutics' stakeholders.
For most companies, including HLS Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for HLS Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, HLS Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 1.0181 | Book Value 2.495 | Operating Margin (0.13) | Profit Margin (0.39) | Return On Assets (0.03) |
HLS |
HLS Therapeutics Debt to Cash Allocation
HLS Therapeutics has accumulated 87.62 M in total debt with debt to equity ratio (D/E) of 50.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. HLS Therapeutics has a current ratio of 1.67, which is within standard range for the sector. Debt can assist HLS Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, HLS Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like HLS Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for HLS to invest in growth at high rates of return. When we think about HLS Therapeutics' use of debt, we should always consider it together with cash and equity.HLS Therapeutics Total Assets Over Time
HLS Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which HLS Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.HLS Therapeutics Debt Ratio | 56.0 |
HLS Therapeutics Corporate Bonds Issued
HLS Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning HLS Therapeutics Use of Financial Leverage
Leverage ratios show HLS Therapeutics' total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of HLS Therapeutics' financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 87.6 M | 51.5 M | |
| Net Debt | 65.7 M | 69 M | |
| Short Term Debt | 5.2 M | 4.7 M | |
| Long Term Debt | 82 M | 86.2 M | |
| Long Term Debt Total | 96.3 M | 91.3 M | |
| Short and Long Term Debt | 4.7 M | 9.2 M | |
| Net Debt To EBITDA | 5.01 | 5.26 | |
| Debt To Equity | 0.89 | 0.73 | |
| Interest Debt Per Share | 2.96 | 1.54 | |
| Debt To Assets | 0.41 | 0.56 | |
| Long Term Debt To Capitalization | 0.46 | 0.25 | |
| Total Debt To Capitalization | 0.47 | 0.26 | |
| Debt Equity Ratio | 0.89 | 0.73 | |
| Debt Ratio | 0.41 | 0.56 | |
| Cash Flow To Debt Ratio | 0.18 | 0.17 |
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against HLS Stock
The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.